NovaCell—Villanova’s Center for Cellular Engineering

The Genesis

In August 2017, the U.S. Food and Drug Administration issued a historic action making the first gene therapy available in the United States, ushering in a new approach to the treatment of cancer and other serious and life-threatening diseases. The life-changing potential of gene therapy products is undeniable, but the cost, which could be 20 or 30 times the annual wages of the typical American, according to the director of the Center for Health Policy and Outcomes at the Memorial Sloan Kettering Cancer Center, will dramatically limit their reach.

Villanova University is poised to make its own contributions to gene and cell therapy through NovaCell, the Center for Cellular Engineering. Founded in 2018, NovaCell’s mission is to lead efforts to improve cell and gene therapy products, and the bioprocesses used to make them.

Villanova is the ideal location for the Center given its proximity to major medical research hospitals, as well as pharmaceutical companies working on cell therapy products.

Read the official press release about the launch of NovaCell, the Center for Cellular Engineering.

Current Research

Title: Evaluating the effects of cryoformulations and freezing rates on cryopreservation of T cells
Sponsor: GlaxoSmithKline
Start Date: 2019
Investigator: Dr. Jens Karlsson
Description: Research will focus on assessment and prevention of intracellular ice formation during cryopreservation, and will use Villanova’s unique high-speed imaging cryomicroscopy facility to detect the ultra-rapid intracellular freezing events.

Title: Development of Microbioreactors for CART applications
Sponsor: National Institutes of Health subaward
Start Date: 2019
Investigators: Redbud Labs, Inc. with Dr. William Kelly
Description: Focus on improving the bioreactors used to provide controlled delivery of nutrients and biomimetic stimuli in order to influence T-cell growth.

Title: A Transcriptome-based  Model for Improved CAR-T Therapy
Sponsor: National Institute for Innovation in Manufacturing Biopharmaceuticals
Start Date: 2019
Investigators: Dr. William Kelly (PI) with Dr. Zuyi “Jacky” Huang (co-PI) and Redbud Labs, Inc.
Cell growth rate is a limiting factor in CAR-T therapy research. This grant will support the optimum configuration of Redbud’s bioreactor technology, testing T cells under a variety of conditions and different mediums, and developing a mathematical model that can predict cell growth rate based on conditions.

Title: Manipulating the Innate Immune Response to Improve Gene Therapy
Sponsor: National Science Foundation, CAREER grant
State Date
: 2017
: Dr. Jacob Elmer
: The goal of this project is to improve gene therapy by identifying and modifying the genes involved in the immune response to extraneous DNA in several cancer cell lines. Such an approach is expected to enhance gene delivery by inhibiting the target genes with both small molecule inhibitors and inhibitor proteins.

NovaCell News

NovaCell researcher Dr. Jens Karlsson, professor of Mechanical Engineering, co-authored “FTIR Analysis of
Molecular Changes Associated with Warming Injury in Cryopreserved Leukocytes” with Mian Wang and Alptekin Aksan

(2019). The article appeared in Langmuir, 35(23), 7552-7559.

NovaCell hosted a Cancer Awareness Cookout last Thursday  Nov 16, 2019.  Thanks to Christian Jones for coming down and talking about the great "Wolfpack Fights Cancer" event that he organizes every year.

Associate Professor of Chemical Engineering Dr. Jacky Huang’s Biological and Environmental Systems Engineering group recently published a paper in the journal Processes detailing a modeling-based strategy to combat cytokine release syndrome, which is a deadly side effect found in immunotherapy patients. More

NovaCell graduate students recently volunteered at the Ronald McDonald House through a new outreach program called HEART. More

NovaCell—Villanova’s Center for Cellular Engineering

NovaCell Director Dr. William Kelly

Dr. William Kelly

Dr. William Kelly has expertise in scale up and bioprocessing of cell culture products, and has extensive experience working with pharmaceutical companies to improve manufacturing processes and practices.

Contact NovaCell:

Dr. William Kelly, Director

(610) 519-4947